MSB 3.21% $1.13 mesoblast limited

banter and General Discussion, page-4757

  1. 17,010 Posts.
    lightbulb Created with Sketch. 2412
    If there is a delay in re-submission, you should be thinking about what's gone wrong.
    Previously they tried to keep secret that the potency assay previously described didn't work, until Dr Rose let the cat out of the bag.

    So I would guess that the data from the old potency assay isn't particularly convincing and they don't know what to do about it. Likely they are slicing and dicing the data every which way to try and find something that they can show to the FDA and hope they don't ask too many questions or want to see the raw data...
    IMO that's the most likely hiccup.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.